Levemir FlexTouch insulin pen receives approval from Health Canada for treatment of diabetes

Published on October 19, 2013 at 3:11 AM · No Comments

Novo Nordisk today announced that Health Canada has approved Levemir® FlexTouch®, a disposable prefilled insulin pen containing Levemir® (insulin detemir). Levemir® FlexTouch® has been designed to improve ease of use for insulin administration and to help decrease barriers to good treatment adherence for Canadians living with type 1 and type 2 diabetes mellitus (diabetes).

The approval was also announced at the 2013 Vascular Conference in Montreal, Quebec.

Levemir® FlexTouch® features a push-button that does not extend at any set dose and a unique spring-loaded mechanism, in which the injection is driven by a torque spring rather than the user's thumb pressure.1  The torque spring is loaded as the dose is set and the spring energy is activated by depressing the push-button. As a result, the injection force of FlexTouch® is significantly lower than other widely used prefilled pens.2  In 2012, Novo Nordisk announced the Health Canada approval of NovoRapid® FlexTouch®, which provided Canadians living with diabetes with the first prefilled insulin pen without a push-button extension for NovoRapid® (insulin aspart).3

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post